公开(公告)号：US06613878B1

公开(公告)日：2003-09-02

申请号：US08945645

申请日：1998-07-31

申请人： Lynne S. Cox ,  David P. Lane ,  Emma Warbrick ,  David M. Glover

发明人： Lynne S. Cox ,  David P. Lane ,  Emma Warbrick ,  David M. Glover

IPC分类号： A61K3808

CPC分类号： C12N9/22 ,  A61K38/00 ,  C07K14/4738

摘要： Fragments of Fen1 that interact with PCNA are disclosed, together with the use of such fragments or mimetics of Fen1 in methods of screening for compounds useful in treating disorders in which PCNA is implicated. In particular, substances which have the property of binding to PCNA are disclosed, said substances comprising: (i) a fragment of the Fen1 protein containing a peptide of 89 amino acids from the C-terminal region or an active portion thereof; or, (ii) a fragment of the Fen1 protein containing the sequence motif QGRLDxFF; or, (iii) a functional mimetic of said protein fragments; where “x” is preferably the selected form the amino acids S, D or G.

摘要翻译： 公开了与PCNA相互作用的Fen1片段，以及在筛选可用于治疗PCNA所涉及的疾病的化合物的方法中使用Fen1的这种片段或模拟物。 特别地，公开了具有与PCNA结合的性质的物质，所述物质包括：（i）含有C末端区域或其活性部分的89个氨基酸的肽的Fen1蛋白的片段; 或（ii）含有序列基序QGRLDxFF的Fen1蛋白的片段; 或（iii）所述蛋白质片段的功能模拟物;其中“x”优选为所选形式的氨基酸S，D或G.

公开(公告)号：US20030143647A1

公开(公告)日：2003-07-31

申请号：US10253867

申请日：2002-09-24

申请人： University of Pittsburgh of the Commonwealth System of Higher Education

发明人： Olivera J. Finn ,  Henry Kao ,  Donald Hunt ,  Jarrod A. Marto

IPC分类号： G01N033/574 ,  A61K039/00

CPC分类号： G01N33/57484 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/5158 ,  C07K14/4738

摘要： The invention provides a method of priming T cells against tumor antigens comprising by obtaining nanullve CD4null or CD8null T cells from at least one healthy individual, obtaining at least one protein or peptide from at least one cancerous cell; obtaining antigen presenting cells (APCs), culturing the APCs with the at least one protein or peptide, and adding the T cells to the culture of the APCs. The primed T cells can then be employed to identify the antigens or therapeutically as prophylaxis or treatment for cancers. The invention also provides cyclin molecules, and fragments derived from cyclin molecules, as tumor antigens. The invention provides a method for diagnosing a malignant or pre-malignant condition within a patient. The invention also provides a method for vaccinating a patient against malignancies comprising introducing a protein or peptide consisting essentially of all or an immunogenic fragment of a cyclin protein into the patient.

摘要翻译： 本发明提供一种针对肿瘤抗原引发T细胞的方法，包括通过从至少一个健康个体获得初始CD4 +或CD8 + T细胞，从至少一种癌细胞获得至少一种蛋白质或肽; 获得抗原呈递细胞（APC），用至少一种蛋白质或肽培养APC，并将T细胞加入APC培养物中。 然后，引发的T细胞可用于鉴定抗原或治疗性地作为癌症的预防或治疗。 本发明还提供细胞周期蛋白分子和衍生自细胞周期蛋白分子的片段作为肿瘤抗原。 本发明提供了一种用于诊断患者内恶性或恶性前状况的方法。 本发明还提供了一种针对恶性肿瘤接种患者的方法，包括将基本上由细胞周期蛋白的全部或免疫原性片段组成的蛋白质或肽引入患者体内。

公开(公告)号：US20030118600A1

公开(公告)日：2003-06-26

申请号：US10152212

申请日：2002-05-20

申请人： FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH

发明人： Johannes Gerdes ,  Thomas Scholzen ,  Claudia Wohlenberg

IPC分类号： A61K048/00 ,  C12P021/02 ,  C12N005/06 ,  C07H021/04 ,  A61K039/00 ,  C07K014/47

CPC分类号： C12N15/87 ,  A61K38/00 ,  C07K14/4738 ,  C07K2319/00

摘要： The invention relates to the use of a carboxy-terminal fragment of the Ki-67 protein or of an active part, fragment or homologue thereof as a compound that can be used for intracellular transfer and for the introduction in and the release by the cells. The invention further relates to transfer compounds that contain the above-mentioned Ki-67 protein and to the vectors encoding the same. The invention also relates to corresponding pharmaceutical compositions and to the use of the transfer protein as an excipient or active agent in the treatment of diseases.

摘要翻译： 本发明涉及Ki-67蛋白或其活性部分，其片段或同源物的羧基末端片段作为可用于细胞内转移和引入细胞释放的化合物的用途。 本发明还涉及含有上述Ki-67蛋白质的转移化合物及其编码载体。 本发明还涉及相应的药物组合物以及转运蛋白作为赋形剂或活性剂在治疗疾病中的用途。

公开(公告)号：US06569658B1

公开(公告)日：2003-05-27

申请号：US09645791

申请日：2000-08-24

申请人： Ying Luo ,  C. Alan Fu ,  Mary Shen

发明人： Ying Luo ,  C. Alan Fu ,  Mary Shen

IPC分类号： C12N912

CPC分类号： C07K14/4738

摘要： The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.

摘要翻译： 本发明涉及对细胞周期有影响或与细胞周期有关的新型多肽，核酸和相关分子。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。 本发明还提供了鉴定介导细胞周期生物活性的新型组合物的方法，以及这些组合物在疾病诊断和治疗中的应用。

公开(公告)号：US06562591B1

公开(公告)日：2003-05-13

申请号：US09425324

申请日：1999-10-21

申请人： Ying Luo ,  C. Alan Fu ,  Mary Shen

发明人： Ying Luo ,  C. Alan Fu ,  Mary Shen

IPC分类号： C12P2106

CPC分类号： C07K14/4738

摘要： The present invention is directed to polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.

摘要翻译： 本发明涉及对细胞周期有影响或与细胞周期有关的多肽，核酸和相关分子。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。 本发明还提供了鉴定介导细胞周期生物活性的新型组合物的方法，以及这些组合物在疾病诊断和治疗中的应用。

公开(公告)号：US06544956B1

公开(公告)日：2003-04-08

申请号：US09531727

申请日：2000-03-21

申请人： Benito O. de Lumen ,  Alfredo F. Galvez

发明人： Benito O. de Lumen ,  Alfredo F. Galvez

IPC分类号： A61K4800

CPC分类号： C12N15/8261 ,  A61K38/00 ,  C07K14/415 ,  C07K14/4738 ,  C07K2319/00 ,  C12N15/8263 ,  Y02A40/146 ,  Y10S977/911

摘要： The invention provides methods and compositions of selectively disrupting mitotic function in a target cell demonstrating undesirable mitotic function. Suitable target cells include mammalian, plant and bacterial cells, which cells may be in vitro or in situ. The general methods involve introducing into the target cell an effective amount of a peptide comprising contiguous acidic amino acids, such as Asp or Glu, whereby the undesirable mitotic function of the cell is selectively disrupted. In particular embodiments, the peptide comprises a Gm2S-1 peptide, particularly a lunasin and/or alisin peptide. The peptide may be introduced by transfecting the cell with a nucleic acid encoding the peptide.

摘要翻译： 本发明提供了选择性地破坏靶细胞中有丝分裂功能的方法和组合物，其显示出不期望的有丝分裂功能。 合适的靶细胞包括哺乳动物，植物和细菌细胞，哪些细胞可以在体外或原位。 一般方法包括将有效量的包含连续酸性氨基酸（例如Asp或Glu）的肽引入靶细胞，由此选择性地破坏细胞的不期望的有丝分裂功能。 在具体实施方案中，肽包含Gm2S-1肽，特别是lunasin和/或乳链菌肽。 可以通过用编码肽的核酸转染细胞来引入肽。

公开(公告)号：US06521602B1

公开(公告)日：2003-02-18

申请号：US09516065

申请日：2000-03-01

申请人： Salil Patel ,  James McArthur ,  Jeno Gyuris ,  Michael J. Mendez ,  Mitchell H. Finer

发明人： Salil Patel ,  James McArthur ,  Jeno Gyuris ,  Michael J. Mendez ,  Mitchell H. Finer

IPC分类号： A61K4800

CPC分类号： C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4738 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/10 ,  C07K2319/21 ,  C07K2319/23 ,  C07K2319/42 ,  C07K2319/43 ,  C07K2319/75 ,  C12N15/62 ,  C12N2710/10322 ,  C12N2710/10343 ,  C12N2740/16043 ,  C12N2830/002 ,  C12N2830/60

摘要： Disclosed is a nucleic acid composition consisting essentially of a first nucleic acid sequence encoding a chimeric CDKi protein and a second nudeic acid sequence encoding an adenovirus E4 protein, wherein the first and second nucleic acid sequences are operably linked to at least one regulatory sequence.

摘要翻译： 公开了一种基本上由编码嵌合CDKi蛋白的第一核酸序列和编码腺病毒E4蛋白的第二裸核酸序列组成的核酸组合物，其中第一和第二核酸序列可操作地连接至至少一个调控序列。

公开(公告)号：US20020193325A1

公开(公告)日：2002-12-19

申请号：US09044602

申请日：1998-03-19

发明人： RONALD A. DEPINHO

IPC分类号： A61K048/00

CPC分类号： C07K14/4738 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4746

摘要： The present invention provides a novel method of inhibiting the growth of tumor cells based upon the discovery that p19ARF acts as a suppressor of oncogenic transformation by binding to the MDM2 oncoprotein and blocking MDM2's ability to target associated proteins, such as p53 and Rb, for proteosomal degradation. The method provided by the present invention inhibits the growth of a tumor cell by administering to the cell an effective amount of p19ARF or a mimetic thereof, and p53 to inhibit the growth of the tumor cell. Also provided by the present invention are pharmaceutical composition comprising p19ARF or a mimetic thereof, and/or p53.

摘要翻译： 本发明提供了一种基于p19ARF通过结合MDM2癌蛋白作为致癌转化抑制剂并阻断MDM2靶向相关蛋白（如p53和Rb）的能力的蛋白质体的发现，抑制肿瘤细胞生长的新方法 降解。 本发明提供的方法通过向细胞施用有效量的p19ARF或其模拟物和p53来抑制肿瘤细胞的生长来抑制肿瘤细胞的生长。 本发明还提供了包含p19ARF或其模拟物和/或p53的药物组合物。

公开(公告)号：US06495526B2

公开(公告)日：2002-12-17

申请号：US08902572

申请日：1997-07-29

申请人： Jeno Gyuris ,  Lou Lamphere ,  David H. Beach

发明人： Jeno Gyuris ,  Lou Lamphere ,  David H. Beach

IPC分类号： A61K4800

CPC分类号： C07K14/47 ,  A01K2217/05 ,  A61K38/00 ,  C07K14/4738 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/10 ,  C12N15/62 ,  C12N2799/022 ,  C12N2799/026 ,  C12N2799/027

摘要： The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.

摘要翻译： 本发明涉及细胞周期蛋白依赖性激酶（CDK）的新型抑制剂，特别是CDK /细胞周期蛋白复合物，该抑制剂可用于控制其中引入抑制剂的细胞的增殖和/或分化。

公开(公告)号：US06476193B1

公开(公告)日：2002-11-05

申请号：US09167206

申请日：1998-10-06

申请人： Krishnan Nandabalan ,  Vincent P. Schulz ,  Meija Yang

发明人： Krishnan Nandabalan ,  Vincent P. Schulz ,  Meija Yang

IPC分类号： C07K1400

CPC分类号： C12N9/1205 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4738 ,  C07K2319/00

摘要： The present invention discloses complexes of the Nlk1 protein with proteins identified as interacting with the Nlk1 protein (Nlk1 protein-IPs) by a modified, improved yeast two hybrid assay system. The proteins which were identified to interact with the Nlk1 protein, and thus form complexes, included: TrkA, protein phosphatase 1&agr;, 14-3-3&egr;, &agr;-tropomyosin, vimentin, p0071, Ini-1, IP-1, IP-2, IP-3, IP-4 and IP-5, as well as derivatives, fragments analogs and homologs thereof. Methodologies of screening these aforementioned complexes for efficacy in treating and/or preventing various diseases and disorders, particularly, neoplasia, neurodegenerative disease, hypertrophic cardiomyopathy, viral infections and metabolic diseases and disorders are also disclosed herein.

摘要翻译： 本发明公开了通过修饰的改进的酵母双杂交测定系统将Nlk1蛋白与被鉴定为与Nlk1蛋白（Nlk1蛋白-IPs）相互作用的蛋白质的复合物。 被鉴定为与Nlk1蛋白相互作用，从而形成复合物的蛋白质包括：TrkA，蛋白磷酸酶1α，14-3-3eps，α-原肌球蛋白，波形蛋白，p0071，Ini-1，IP-1，IP-2 ，IP-3，IP-4和IP-5，以及其衍生物，片段类似物和同系物。 本文还公开了筛选这些上述复合物用于治疗和/或预防各种疾病和病症，特别是瘤形成，神经变性疾病，肥大性心肌病，病毒感染和代谢性疾病和病症的方法。